These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 16932077)
21. Dosing and administration of ReoPro (c7E3 Fab). Tcheng JE J Invasive Cardiol; 1994; 6 Suppl A():29A-33A; discussion 51A-54A. PubMed ID: 10155091 [No Abstract] [Full Text] [Related]
22. [Abciximab: a new antiplatelet agent for use in coronary angioplasty]. van den Brand MJ; Simoons ML Ned Tijdschr Geneeskd; 1998 Dec; 142(50):2728-32. PubMed ID: 10065237 [TBL] [Abstract][Full Text] [Related]
24. Platelet glycoprotein IIb/IIIa inhibition and atheroembolism during bypass graft angioplasty: a cup half full. Kereiakes DJ Circulation; 2002 Dec; 106(24):2994-6. PubMed ID: 12473539 [No Abstract] [Full Text] [Related]
25. Chest pain--a strong predictor of adverse cardiac events following precutaneous intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial [EPISENT])]. Robbins MA; Marso SP; Wolski K; Peterson J; Lincoff AM; Brener S Am J Cardiol; 1999 Dec; 84(11):1350-3, A8. PubMed ID: 10614805 [TBL] [Abstract][Full Text] [Related]
26. Preventing coronary restenosis and complications. Holmes DR N Engl J Med; 1997 Jun; 336(24):1748-9. PubMed ID: 9180094 [No Abstract] [Full Text] [Related]
27. Restenosis: is there a pharmacologic fix in the pipeline? Keiser JA; Uprichard AC Adv Pharmacol; 1997; 39():313-51. PubMed ID: 9160119 [TBL] [Abstract][Full Text] [Related]
28. Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation. Brener SJ; Bhatt DL; Moliterno DJ; Schneider JP; Ellis SG; Topol EJ Am J Cardiol; 2003 Dec; 92(12):1468-71. PubMed ID: 14675590 [TBL] [Abstract][Full Text] [Related]
29. EPILOG and CAPTURE trials halted because of positive interim results. Ferguson JJ Circulation; 1996 Feb; 93(4):637. PubMed ID: 8640987 [No Abstract] [Full Text] [Related]
30. [Medical progress exemplified by improvements in the safety coronary angioplasty]. Metzger JP Bull Acad Natl Med; 2012 Oct; 196(7):1361-7; discussion 1367-8. PubMed ID: 23815020 [TBL] [Abstract][Full Text] [Related]
31. Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention. Lefkovits J; Topol EJ Prog Cardiovasc Dis; 1997; 40(2):141-58. PubMed ID: 9327830 [TBL] [Abstract][Full Text] [Related]
32. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Chew DP; Bhatt DL; Lincoff AM; Moliterno DJ; Brener SJ; Wolski KE; Topol EJ Circulation; 2001 Feb; 103(7):961-6. PubMed ID: 11181470 [TBL] [Abstract][Full Text] [Related]
37. Intravenous administration of monoclonal antibody to the platelet GP IIb/IIIa receptor to treat abrupt closure during coronary angioplasty. Anderson HV; Revana M; Rosales O; Brannigan L; Stuart Y; Weisman H; Willerson JT Am J Cardiol; 1992 May; 69(16):1373-6. PubMed ID: 1585878 [No Abstract] [Full Text] [Related]
38. Heparin for coronary angioplasty: high dose, low dose, or no dose? Garachemani A; Meier B Heart; 1998 Jul; 80(1):3-4. PubMed ID: 9764047 [No Abstract] [Full Text] [Related]
39. Local drug delivery systems and prevention of restenosis. Brieger D; Topol E Cardiovasc Res; 1997 Sep; 35(3):405-13. PubMed ID: 9415284 [No Abstract] [Full Text] [Related]